FDA ApprovalThe company expects to submit its MyoVista device for FDA approval, which could lead to significant advancements in their product offerings.
Partnerships And StrategyA shift to software-based solutions, the Mount Sinai partnership, and international agreements are seen as positives.
Revenue OpportunitiesCMS reimbursement for AI-ECG technology paves the way for monetization, creating potential revenue opportunities for HeartSciences.